The stock of Codexis, Inc. (NASDAQ:CDXS) is a huge mover today! About 314,249 shares traded hands or 341.79% up from the average. Codexis, Inc. (NASDAQ:CDXS) has risen 41.96% since March 29, 2016 and is uptrending. It has outperformed by 38.48% the S&P500.
The move comes after 7 months positive chart setup for the $202.82 million company. It was reported on Oct, 31 by Barchart.com. We have $12.57 PT which if reached, will make NASDAQ:CDXS worth $314.37 million more.
Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on November, 2. They expect $-0.14 EPS, down 207.69% or $0.27 from last year’s $0.13 per share. After $0.07 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -300.00% negative EPS growth.
According to Zacks Investment Research, “Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.”
Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.34, from 1.08 in 2016Q1. The ratio is positive, as 14 funds sold all Codexis, Inc. shares owned while 12 reduced positions. 20 funds bought stakes while 17 increased positions. They now own 16.51 million shares or 13.83% more from 14.50 million shares in 2016Q1.
Dimensional Fund Advsrs Ltd Partnership last reported 0% of its portfolio in the stock. Morgan Stanley accumulated 4,520 shares or 0% of the stock. Opaleye Mgmt holds 360,000 shares or 0.83% of its portfolio. Moreover, Manufacturers Life Insur The has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 28,751 shares. Legal & General Grp Public Ltd Liability Corporation holds 6,312 shares or 0% of its portfolio. New York State Common Retirement Fund owns 34,400 shares or 0% of their US portfolio. Moreover, Northern Tru Corp has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 347,068 shares. Blackrock Fund Advsrs holds 0% or 876,101 shares in its portfolio. Wells Fargo Company Mn last reported 0% of its portfolio in the stock. Blackrock Institutional Tru Na owns 1.26M shares or 0% of their US portfolio. Granite Invest Prtn has 0.12% invested in the company for 375,805 shares. The Ontario – Canada-based Financial Bank Of Montreal Can has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Blackrock has 0% invested in the company for 6,710 shares. Deutsche Bank & Trust Ag last reported 0% of its portfolio in the stock. The New York-based Mufg Americas Hldgs has invested 0% in Codexis, Inc. (NASDAQ:CDXS).
Insider Transactions: Since August 3, 2016, the stock had 0 insider purchases, and 5 insider sales for $1.31 million net activity. Another trade for 111,600 shares valued at $474,624 was made by VIVO VENTURES VII – LLC on Thursday, September 8. WOLF DENNIS P had sold 18,000 shares worth $75,974. $53,807 worth of Codexis, Inc. (NASDAQ:CDXS) shares were sold by KELLEY BERNARD J.
More important recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Marketwatch.com which released: “Codexis Inc.” on April 22, 2010, also Seekingalpha.com published article titled: “Can Codexis Maintain Its Clout?”, Businesswire.com published: “Codexis Files Lawsuit against EnzymeWorks and CEO Junhua â€œAlexâ€ Tao for Patent …” on February 22, 2016. More interesting news about Codexis, Inc. (NASDAQ:CDXS) was released by: Seekingalpha.com and their article: “Codexis’ (CDXS) CEO John Nicols on Q2 2016 Results – Earnings Call Transcript” with publication date: August 10, 2016.
CDXS Company Profile
Codexis, Inc., incorporated on January 31, 2002, is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for process development, from research to manufacturing. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Firm have commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. The Company’s pharmaceutical customers, including several of the global pharmaceutical companies, use its technology, services and products in their manufacturing processes and process development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.